Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

sNDA for Nolvadex in DCIS to undergo priority review

March 17, 2000

EGF receptor tyrosine kinase inhibitor selected for clinical testing at Parke-Davis

March 16, 2000

NIH advisory committee approves phase III protocol for Introgen's p53 gene therapy

March 15, 2000

Orphan Medical's Busulfex approved in Israel

March 15, 2000

Additional mechanism of action revealed for Neovastat

March 15, 2000

Alizyme receives notice of allowance, manufacturing license for mucositis product

March 14, 2000

New compounds for cancer developed at Abbott

March 14, 2000

Oxigene and Techniclone join forces to develop new-generation anticancer agents

March 14, 2000

Distamycin used as lead at P&U to design new alkylating agents

March 13, 2000

AEterna cleared to commence phase III trial of AE-941 for treatment of kidney cancer

March 13, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...